Signal Advisors Wealth LLC Trims Stock Position in Waters Corporation $WAT

Key Points

• Signal Advisors Wealth LLC decreased its holdings in Waters Corporation (NYSE:WAT) by 16.7%, now owning 5,128 shares worth approximately $1.79 million.
• Waters Corporation reported Q2 earnings of $2.95 per share, exceeding estimates, with a revenue of $771.33 million, marking an 8.8% year-over-year growth.
• Wall Street analysts have mixed reviews for Waters, with target prices ranging from $375 to $465, reflecting an overall average rating of "Hold".

Signal Advisors Wealth LLC lowered its position in shares of Waters Corporation (NYSE:WAT - Free Report) by 16.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,128 shares of the medical instruments supplier's stock after selling 1,026 shares during the period. Signal Advisors Wealth LLC's holdings in Waters were worth $1,790,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Olde Wealth Management LLC acquired a new stake in Waters in the 1st quarter valued at approximately $25,000. Zions Bancorporation National Association UT acquired a new stake in Waters in the 1st quarter valued at approximately $28,000. IFP Advisors Inc increased its holdings in Waters by 118.9% in the 1st quarter. IFP Advisors Inc now owns 81 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 44 shares during the last quarter. Whipplewood Advisors LLC increased its holdings in Waters by 5,200.0% in the 1st quarter. Whipplewood Advisors LLC now owns 106 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 104 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Waters in the 1st quarter valued at approximately $41,000. Institutional investors and hedge funds own 94.01% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on WAT. UBS Group reissued a "neutral" rating on shares of Waters in a research report on Tuesday, July 15th. Scotiabank reissued a "sector outperform" rating and issued a $465.00 price target on shares of Waters in a research report on Friday, July 11th. Wells Fargo & Company decreased their price target on shares of Waters from $330.00 to $315.00 and set an "equal weight" rating for the company in a research report on Tuesday, August 5th. Jefferies Financial Group set a $385.00 price target on shares of Waters and gave the company a "buy" rating in a research report on Monday, August 4th. Finally, Robert W. Baird decreased their price target on shares of Waters from $374.00 to $352.00 and set an "outperform" rating for the company in a research report on Wednesday, July 16th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $378.73.

Waters Stock Performance

NYSE WAT traded down $4.95 during trading on Friday, reaching $301.43. The company's stock had a trading volume of 2,012,717 shares, compared to its average volume of 586,122. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.22 and a current ratio of 1.75. The firm has a market cap of $17.94 billion, a price-to-earnings ratio of 27.18, a P/E/G ratio of 2.81 and a beta of 1.07. Waters Corporation has a twelve month low of $275.05 and a twelve month high of $423.56. The business's fifty day moving average price is $294.95 and its 200-day moving average price is $330.56.

Waters (NYSE:WAT - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The medical instruments supplier reported $2.95 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.02. Waters had a net margin of 21.71% and a return on equity of 38.60%. The business had revenue of $771.33 million for the quarter, compared to analyst estimates of $745.96 million. During the same period in the previous year, the business posted $2.63 earnings per share. The business's revenue was up 8.8% compared to the same quarter last year. Waters has set its Q3 2025 guidance at 3.150-3.250 EPS. FY 2025 guidance at 12.950-13.050 EPS. As a group, analysts anticipate that Waters Corporation will post 12.86 EPS for the current fiscal year.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.